MedTrace Logo

Prevention of CF Exacerbation in Childhood: PREVEC Study

NCT01241890 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 49

Last updated 2015-07-17

No results posted yet for this study

Summary

Pulmonary exacerbations of CF are an important cause for the experienced disability of patients, respiratory symptoms, and decreases in lungfunction, which require antibiotic therapy at home or in the hospital. Therefore, prevention of exacerbations in CF is important. The aim of this study was to assess the predictive properties of inflammatory markers in exhaled breath for pulmonary exacerbations in children with CF. In addition the reliability of home monitor assessments of symptoms and lungfunction was investigated.

Conditions

  • Cystic Fibrosis
  • Children
  • Exhaled Breath Condensate
  • Non-invasive Inflammatory Markers
  • Volatile Organic Compounds
  • Home Monitoring
  • Quality of Life

Sponsors & Collaborators

  • NCFS

    collaborator UNKNOWN

  • Chiesie Pharmaceuticals B.V.

    collaborator UNKNOWN

  • Maastricht University Medical Center

    lead OTHER

Principal Investigators

  • E Dompeling, PhD MD · Maastricht University Medical Centre

Eligibility

Min Age
5 Years
Max Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-10-31
Primary Completion
2013-08-31
Completion
2014-07-31

Countries

  • Netherlands

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01241890 on ClinicalTrials.gov